Etretinate Augments Interferon Beta-1b Effects on Suppressor Cells in Multiple Sclerosis
نویسندگان
چکیده
منابع مشابه
Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis.
BACKGROUND Interferon beta treatment is only partially effective in multiple sclerosis (MS) suggesting a potential role for adjunctive therapies. Retinoids can augment the clinical efficacy of type 1 interferons in patients with cancer. We reasoned that the same might hold in MS. Interferon beta-1b added to peripheral blood mononuclear cells in vitro partially reverses the CD8 suppressor cell d...
متن کاملApplication of Interferon Beta-1b in Multiple Sclerosis
Recombinant interferon beta-1b (IFNβ-1b) was the first approved disease-modifying therapy for patients with multiple sclerosis (MS) by the world regulatory agencies for medical drugs and devices. IFNβ-1b significantly decreases the inflammatory component of MS but still has doubtable effect on the neurodegenerative component. This article appraises the beneficial effects of IFNβ-1b on clinical ...
متن کاملInterferon-beta-1b protects against multiple sclerosis-induced endothelial cells apoptosis.
Disruption of the blood-brain-barrier (BBB) due to endothelial cell (EC) injury is an essential step in formation of multiple sclerosis (MS) lesions. We investigated the role of endothelial cell (EC) apoptosis in the pathophysiology of MS, studying the therapeutic effect of IFN-beta-1b against MS sera-induced endothelial apoptosis. Human umbilical vein endothelial cells were treated with sera f...
متن کاملP 52: Interferon beta-a1 vs. Teriflunomide for Multiple Sclerosis
Multiple sclerosis (MS) is an inflammatory disorder, in which neurons in central nervous system (CNS) become demyelinated .MS is named for its formation of plaques due to sclerosis of myelin. Variable degree of demyelination results in mild, mediate or severe symptomatic episodes of this disease. It is commonly characterized by recurrent relapses and often followed by severe neurological disabi...
متن کاملCurrent Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis
Interferon (IFN) beta-1b was the first disease-modifying therapy to be approved for the treatment of multiple sclerosis (MS), and over 21 years of follow-up data demonstrate its efficacy and long-term safety profile. Following recent regulatory approvals in the USA and European Union, IFN beta-1b is now one of the seven disease-modifying therapies [intramuscular IFN beta-1a; subcutaneous (SC) I...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Neurology
سال: 2001
ISSN: 0003-9942
DOI: 10.1001/archneur.58.1.87